| |
Financial Year 2009 - 2010
Quarter I
(June 2009)
Financial Year 2008 - 2009
Quarter IV
(March 2009)
Quarter III
(December 2008)
Quarter II
(September 2008)
Quarter I
(June 2008)
Financial Year 2007 - 2008
Quarter IV
(March 2008)
Quarter III
(December 2007)
Quarter II
(September 2007)
Quarter I
(June 2007)
Financial Year 2006 - 2007
Quarter IV
(March 2007)
Quarter III
(December 2006)
Quarter II
(September 2006)
Quarter I
(June 2006)
Financial Year 2005 - 2006
Quarter IV
(March 2006)
Quarter III
(December 2005)
Quarter II
(September 2005)
Quarter I
(June 2005)
Financial Year 2004 - 2005
Quarter IV
(March 2005)
Quarter III
(December 2004)
Quarter II
(September 2004)
Quarter I
(June 2004)
Financial Year 2003 - 2004
Quarter IV
(March 2004)
Quarter III
(December 2003)
Quarter II
(September 2003)
Quarter I
(June 2003)
Financial Year 2002 - 2003
Quarter IV
(March 2003)
Quarter III
(December 2002)
Quarter II
(September 2002)
Quarter I
(June 2002)
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR
ENDED 31ST MARCH 2009
| (Rs. in Lakhs) |
| Sl. No |
Particulars |
Year ended 31st March |
| 2009 (Audited) |
2008 (Audited) |
01.
02.
03.
04.
05.
06.
07.
08.
09.
10.
11.
12.
13.
14.
15.
16.
17.
|
a) Net Sales / Income from
Operations
- Sales (net)
b) Other Operating Income
- Other Income from Operations
- Income from Potential
patent infringement suit
Total
Expenditure
a) Increase in Stock
in trade and work
in progress
b) Materials Consumed
c) Purchase of traded goods
d) Employee cost
e) Research and Development Expenditure (including depreciation & amortization)
f) Depreciation
& Amortization (excluding R & D)
g)Other Expenditure
Total
Profit from operations
before other income,
interest, exceptional items (1-2)
Other Income
Profit before Interest &
Exceptional Items (3+4)
Interest and Finance Cost
Profit after Interest but
before Exceptional Items (5-6)
Provision for impairment of goodwill
Profit / (Loss) before tax
and after exceptional
item (7-8)
Tax expense
Profit /(Loss) after Tax but
before Minority Interest and share
in Associate (9-10)
Less : Minority Interest
share of Profit / Loss
Less : Share of Profit / Loss
in Associate
Net Profit / (Loss) after
Tax (11-12-13 )
Paid-up equity share capital (Face value - Rs.2 each)
Reserves excluding revaluation
reserves
Earning Per Share (Not
annualised) - (Face Value
- Rs.2 each)
On Profit / (Loss) after Tax :
- Before Exceptional Item
- Basic ( Rs )
- Diluted ( Rs )
- After Exceptional Item
- Basic ( Rs )
- Diluted ( Rs )
|
227,385
483
1,346
229,214
(1,061)
78,583
35,406
24,293
21,423
7,006
39,179
204,829
24,385
2,572
26,957
14,710
12,247
-
12,247
8,784
3,463
(436)
(28)
2,999
3,092
62,175
1.94
1.94
1.94
1.94
|
172,807
661
2,691
176,159
(8,168)
66,012
32,201
18,825
14,233
6,055
31,886
161,044
15,115
2,439
17,554
9,654
7,900
48,712
(40,812)
5,297
(46,109)
419
(3)
(45,693)
3,092
58,418
1.96
1.95
(29.59)
(29.59)
|
Segment Information:
Net Segment Revenue:
-Pharmaceuticals
-Medical Supplies
Total
Segment Results :
Profit before tax and interest
from each segment
-Pharmaceuticals
-Medical Supplies
Total
Less: Interest & Finance cost
Profit / Loss before tax and
Exceptional Items
Capital Employed :
-Pharmaceuticals
-Medical Supplies
-Unallocated
Total
|
207,433
19,952
227,385
25,911
1,046
26,957
(14,710)
12,247
178,675
7,009
85,745
271,429
|
157,067
15,740
172,807
16,983
571
17,554
(9,654)
7,900
149,770
4,825
79,771
234,366
|
|
| Notes : |
The above results were reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 25th June 2009. The figures for the previous year have been rearranged/regrouped wherever necessary to conform to current period's presentation. "Matrix Laboratories Limited (Matrix) had entered into agreements in October 2008 for the termination of the joint venture agreements with Aspen Pharmacare Holdings Limited (“Aspen”). The Astrix Laboratories Limited (Astrix) and Fine Chemicals Corporation (Pty) Limited (FCC) joint ventures are held 50:50 by Aspen and Matrix along with their respective subsidiaries. Under the terms of the new agreement, 50% Matrix stake in FCC would be bought back by Aspen and 50% Aspen stake in Astrix would be bought back by Matrix. Matrix has assigned its right to acquire 50% stake in Astrix to its parent company to the extent of 49% and fellow subsidiary to the extent of 1%. The transaction has been closed with effect from May 31, 2009. "MP Laboratories (Mauritius) Limited (MP Laboratories), a wholly owned subsidiary of Mylan Inc., and one of the Promoters of the Company had initiated voluntary delisting of the shares of the Company from the Bombay Stock Exchange (BSE) and National Stock Exchange of India Limited (NSE) (together “Stock Exchanges”) in accordance with the Securities and Exchange Board of India (Delisting of Securities) Guidelines, 2003 (‘the Delisting Offer’). On 1st June, 2009, MP Laboratories announced the acceptance of the discovered price of Rs. 211/- per share (“Exit Price”) established by the reverse book building process in the Delisting Offer. Under the Delisting Offer, MP Laboratories has acquired 27,053,416 equity shares aggregating to 17.50% of the paid-up share capital of the Company, thereby increasing the Promoters shareholding to 93.63% of the paid-up share capital of the Company. Subsequent to this, the Company has allotted 1,725,170 equity shares of Rs.2/- each to Matrix ESOP Trust on 21st June 2009. Consequent to this allotment, the paid-up share capital of the Company increased to Rs. 312,677,622 comprising of 156,338,811 equity shares of Rs. 2/- each. The Company will make requisite applications to the stock exchanges for delisting of the shares of the Company."
|
| |
For and on behalf of the Board
|
Place : Secundrabad
Date : 25th June 2009 |
S. Srinivasan
Managing Director & Chief Executive Officer
|
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED
31ST MARCH 2009
| (Rs. in Lakhs ) |
| Sl. No |
Particulars |
| Year Ended 31st March |
Year Ended 31st March |
|
| 2009 ( Audited) |
2008 ( Audited) |
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
|
a)Net Sales / Income from Operation
-Exports
-Domestic
b) Other Operating Income
- Other Income from Operations
- Income from Potential
patent infringement suit
Total
Expenditure
a) Increase in Stock
in trade and work
in progress
b) Materials Consumed
c) Purchase of traded goods
d) Employee cost
e) Research and Development Expenditure (including depreciation & amortization)
f) Depreciation
& Amortization (excluding R & D)
g)Other Expenditure
Total
Profit from operations
before other income,
interest, exceptional items (1-2)
Other Income
Profit before Interest &
Exceptional Items (3+4)
Interest and Finance Cost
Profit after Interest but
before Exceptional Items (5-6)
Provision for diminution in
the value of investment
in subsidiary
Profit/(Loss) before tax
and after exceptional
item (7-8)
Tax expense
Net Profit/(Loss) after
tax (9-10)
Paid-up equity share capital
(Face value - Rs.2/- each)
Reserves excluding
revaluation reserves
Earning Per Share (EPS)
On Profit / (Loss) after Tax :
Before Exceptional Item
- Basic (Rs.)
- Diluted (Rs.)
After Exceptional Item
- Basic (Rs.)
- Diluted (Rs.)
Public Share holding
- Number of shares
- Percentage of shareholding
Promoters and Promoter Group Shareholding
- Pledged / Encumbered
- Non - encumbered
|
123,998
23,905
965
1,346
150,214
(6,663)
74,800
2,336
9,701
17,765
3,558
19,513
121,010
29,204
2,185
31,389
5,692
25,697
-
25,697
6,802
18,895
3,092
83,840
12.22
12.22
12.22
12.22
36,911,189
23.87%
Nil
Nil
|
62,066
31,797
1,322
2,691
97,876
(7,258)
53,412
354
7,038
10,641
2,954
15,896
83,037
14,839
2,018
16,857
2,727
14,130
40,118
(25,988)
3,848
(29,836)
3,092
64,899
6.66
6.64
(19.32)
(19.32)
36,876,696
23.85%
Nil
Nil
|
|
| Notes : |
- The above results were reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 25th June 2009.
- The activities of the Company relate to only one business segment i.e. Pharmaceuticals.
- Tax expense includes Current tax Rs.4452 lakhs (2007-08 Rs.1585 lakhs), adjustment relating to past years of Rs.152 lakhs (2007-08 Rs.551 lakhs), Deferred Tax Rs.2537 lakhs (2007-08 Rs.1279 lakhs), Fringe benefit tax Rs.93 lakhs (2007-08 Rs.210 lakhs) and is net of MAT credit available of Rs.432 lakhs (2007-08 Rs.(223) lakhs).
- The figures for the previous year have been rearranged/regrouped wherever necessary to conform to current period's presentation.
- Summary of Investor Complaints :
Opening : nil Received during the quarter : nil Resolved : na Closing : nil"
- During the year, 26775 Equity shares of Rs.2/- each at premium of Rs.141.13 were alloted on exercise of stock options under the Employee stock options scheme
- The Board of Directors at their meeting held on 29th October 2008 & 28th January 2009 approved conversion of 6718 & 1000 partly paid up Equity Shares of Rs.2/- each into fully paid up shares respectively.
- Matrix Laboratories Limited (Matrix) had entered into agreements in October 2008 for the termination of the joint venture agreements with Aspen Pharmacare Holdings Limited (“Aspen”). The Astrix Laboratories Limited (Astrix) and Fine Chemicals Corporation (Pty) Limited (FCC) joint ventures are held 50:50 by Aspen and Matrix along with their respective subsidiaries. Under the terms of the new agreement, 50% Matrix stake in FCC would be bought back by Aspen and 50% Aspen stake in Astrix would be bought back by Matrix. Matrix has assigned its right to acquire 50% stake in Astrix to its parent company to the extent of 49% and fellow subsidiary to the extent of 1%. The transaction has been closed with effect from May 31, 2009.
- MP Laboratories (Mauritius) Limited (MP Laboratories), a wholly owned subsidiary of Mylan Inc., and one of the Promoters of the Company had initiated voluntary delisting of the shares of the Company from the Bombay Stock Exchange (BSE) and National Stock Exchange of India Limited (NSE) (together “Stock Exchanges”) in accordance with the Securities and Exchange Board of India (Delisting of Securities) Guidelines, 2003 (‘the Delisting Offer’). On 1st June, 2009, MP Laboratories announced the acceptance of the discovered price of Rs. 211/- per share (“Exit Price”) established by the reverse book building process in the Delisting Offer. Under the Delisting Offer, MP Laboratories has acquired 27,053,416 equity shares aggregating to 17.50% of the paid-up share capital of the Company, thereby increasing the Promoters shareholding to 93.63% of the paid-up share capital of the Company. Subsequent to this , the Company has allotted 1,725,170 equity shares of Rs. 2/- each to Matrix ESOP Trust on 21st June 2009. Consequent to this allotment, the paid-up share capital of the Company increased to Rs. 312,677,622 comprising of 156,338,811 equity shares of Rs. 2/- each. The Company will make requisite applications to the stock exchanges for delisting of the shares of the Company.
|
| |
For and on behalf of the Board
|
Place : Secunderabad
Date : 25th June 2009 |
S.Srinivasan
Managing Director & Chief Executive Officer
|
|
|
